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Abstract
Background: Epigenetic silencing of the RAS association domain family 1A (RASSF1A) tumor
suppressor gene promoter has been demonstrated in renal cell carcinoma (RCC) as a result of
promoter hypermethylation. Contradictory results have been reported for RASSF1A methylation
in normal kidney, thus it is not clear whether a significant difference between RASSF1A methylation
in normal and tumor cells of the kidney exists. Moreover, RASSF1A expression has not been
characterized in tumors or normal tissue as yet.
Results:  Using combined bisulfite restriction analysis (COBRA) we compared RASSF1A
methylation in 90 paired tissue samples obtained from primary kidney tumors and corresponding
normal tissue. Bisulfite sequence analysis was carried out using both pooled amplicons from the
tumor and normal tissue groups and subclones obtained from a single tissue pair. Expression of
RASSF1A was analyzed by the use of tissue arrays and immunohistochemistry. We found
significantly increased methylation in tumor samples (mean methylation, 20%) compared to
corresponding normal tissues (mean methylation, 11%; P < 0.001). Densely methylated sequences
were found both in pooled and individual sequences of normal tissue. Immunohistochemical
analysis revealed a significant reduced expression of RASSF1A in most of the tumor samples.
Heterogeneous expression patterns of RASSF1A were detected in a subgroup of histologically
normal tubular epithelia.
Conclusion:  Our methylation and expression data support the hypothesis that RASSF1A  is
involved in early tumorigenesis of renal cell carcinoma.
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Background
Renal cell carcinoma (RCC) accounts for 2–3% of human
malignancies and is the seventh most frequent cause of
tumor-dependent death among men [1,2]. The most com-
mon histological subtypes of sporadic kidney tumors are
clear cell RCC (CC-RCC) and papillary tumors [3].
Tumorigenesis of CC-RCC is frequently associated with
loss and/or alteration of the short arm of chromosome 3
[4]. At least two tumor suppressors are localized on 3p21-
3p25, the von Hippel-Lindau (VHL) and the RAS associa-
tion domain family 1A (RASSF1A) genes, both found to
be altered in sporadic RCC. Chromosomal alterations,
point mutations and epigenetic silencing have been
described to affect VHL function [5-7], while RASSF1A has
frequently been detected to undergo promoter hyper-
methylation and epigenetic silencing in CC-RCC [8-11].
RASSF1A is functionally involved in cell cycle control,
microtubule stabilization, cellular adhesion and motility
as well as apoptosis (reviewed in [12]). Therefore, deple-
tion of RASSF1A is associated with accelerated mitotic
progression and an increased risk for chromosomal
defects [13-15], enhanced cellular motility [16] and with
increased tumor susceptibility in knock-out mice [17].
The multifaceted function of RASSF1A as well as its fre-
quently detected epigenetic silencing suggests an essential
role in carcinogenesis. Therefore, findings regarding
RASSF1A methylation in histopathologically normal kid-
ney tissue isolated adjacent to tumor tissue or from
autopsy samples [8,18,19] might be indicative for an
involvement of RASSF1A  in the early tumorigenesis of
CC-RCC. On the other hand, significant methylation in
normal tissue has not been described in other reports
[9,10,20] and a quantitative study questions that signifi-
cant differences in RASSF1A methylation can be found
comparing methylation levels in CC-RCC and corre-
sponding normal tissue samples [11].
The detection of a methylation frequency in tumor tissue
matching that in normal tissue would indicate that
RASSF1A methylation in kidney is more likely to be inde-
pendent from CC-RCC tumorigenesis. Conversely, if
methylation could be found in normal tissue, which
expands following tumor development, a role of RASSF1A
in early tumorigenesis is implied. Thus, both quality and
quantitative extent of methylation in histopathologically
normal and tumoral tissue of tumor-bearing kidney
requires systematic analysis to demonstrate whether sig-
nificant methylation can be found in normal cells and a
substantially increased methylation can be detected
within neoplastic cells. Moreover, considering that so far
the presence of RASSF1A protein has been analyzed solely
in fully transformed or embryonic cell lines [14,16], it is
an important issue to examine whether methylation levels
can be correlated to a corresponding expression of
RASSF1A in normal and tumor tissues.
In the present study, we have quantitatively measured
promoter methylation of the RASSF1A  gene in paired
samples of CC-RCC and corresponding normal renal tis-
sue. Furthermore, the presence of RASSF1A protein in
tumors and histopathologically normal parenchyma was
analyzed using tissue arrays and immunohistochemistry.
Methylation was found to be significantly increased
within tumor cells of tissue pairs analyzed. Correspond-
ingly, almost complete loss of RASSF1A expression was
observed in tumor cells, while normal tubular epithelial
cells largely demonstrated strong immunopositivity.
However, a subgroup of tissues exhibited a heterogeneous
expression pattern including partial loss of RASSF1A pro-
tein.
Results
Quantitation of RASSF1A methylation in paired tumoral 
and normal tissue samples
Methylation was first quantitatively analyzed in tumor vs.
paired normal tissue from each individual patient using
COBRA (Fig. 2), Fig. 3a).
It is obvious from Fig. 3a that most tumors and normal tis-
sues demonstrate relative methylation levels above the
analytical detection limit, however, a relative increase of
methylation in tumors when compared to the paired nor-
mal tissue was observed in 39 (86.7%) of 45 tumors (Fig.
3b). This finding is statistically significant (t-test for
paired samples, P < 0.001). Note that five tissue pairs
demonstrated an apparently decreased relative methyla-
tion in tumors which possibly can be deduced from small
measurement variations considering that the correspond-
ing methylation levels approximated the methodical limit
of detection.
Mean degrees of methylation of 20% and 11% were deter-
mined for the tumoral and normal tissues.
Bisulfite sequence analysis for comparison of tumoral and 
normal tissues
Bisulfite sequencing analysis was carried out using in each
case 50 subclones obtained from an individual normal
and tumoral tissue pair following bisulfite conversion and
amplification (Fig. 4). We found 102 (12.8%) and 165
(20.6%) of totally analyzed 800 CpG sites to be methyl-
ated in normal and paired tumoral tissue samples, respec-
tively (P < 0.001, chi-square test). Dense promoter
methylation of more than 10 methylated CpG sites per
clone was more frequently found in the tumor sample (n
= 11) when compared to the paired normal tissue (n = 1;
see Fig. 5).Molecular Cancer 2007, 6:49 http://www.molecular-cancer.com/content/6/1/49
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In addition to the sequence analysis of the individual kid-
ney tissue pair, we conducted an in-group sequence com-
parison of pooled amplicons obtained from the tumor
and normal tissues following conversion, amplification
and normalization of DNA. Thirty-five (5.5%) and 67
(10.5%) of 640 CpG sites analyzed in total were found to
be methylated in the normal and tumor tissue group,
respectively (Fig. 5). Assuming each CpG methylation as
an independent event, statistical analysis showed that
tumor and normal tissue groups demonstrated significant
differences in methylation frequency (P < 0.001, chi-
square test).
Analysis of RASSF1A promoter methylation and RASSF1A 
expression in CaSki and HEK293 cell lines
To detect RASSF1A protein in paraffin embedded tumoral
and normal kidney tissue we first examined the specificity
of the RASSF1A antibody using paraffin embedded sedi-
ments of control cell lines CaSki and HEK293. We found
strong immunopositivity in the cytoplasm of CaSki cells
(Fig. 6a[i]). This corresponds with a lack of RASSF1A pro-
moter methylation as detected by COBRA (Fig. 6a). More-
over, immunopositivity can be specifically blocked by the
peptide used for immunization (Fig. 6a[ii]). On the con-
trary, we detected almost complete methylation of
RASSF1A  in the embryonic kidney cell line HEK293,
which is associated with significantly decreased cytoplas-
mic immunopositivity (Fig. 6b[i]). As expected this find-
ing is not affected by peptide blocking of the antibody
(Fig. 6b[ii]). Faint nuclear positivity, appears as heteroge-
neous pattern in antibody incubations of HEK293 inde-
pendently of the presence of a blocking peptide,
suggesting a residual unspecific nuclear binding of the
polyclonal antibody. However, only cytoplasmic immu-
nopositivity has been considered for evaluation of tissue
sections.
Detection of RASSF1A protein in tumoral and normal 
tissue samples of the kidney
Using immunohistochemistry and tissue arrays obtained
from paraffin embedded renal tissue samples we analyzed
60 tissue pairs for expression of RASSF1A. We found that
33 (55%) of tumors demonstrate to a great extent loss of
cytoplasmic RASSF1A protein corresponding to a labeling
index of less than 10% of immunopositive stained tumor
cells (Fig. 6c). In contrast, the vast majority of normal
tubular epithelial cells showed strong cytoplasmic signals
for RASSF1A protein (Fig. 6d). However, a subgroup of
normal tissues was identified to exhibit loss of immunop-
ositivity in some of the morphologically normal renal
tubular epithelia (Fig. 6e). Moreover, a significant hetero-
geneity of signals appearing as a mosaic-like staining pat-
tern was observed within single renal tubules (Fig. 6f).
Note that both inter- and intratubular heterogeneous
expression of RASSF1A has also been observed using
immunofluorescence detection and the mouse mono-
clonal antibody (data not shown).
Discussion
RASSF1A promoter methylation has been shown to be
associated with gene silencing in RCC [8,9]. However, dis-
cordant results were reported for RASSF1A  promoter
methylation occurring in tumor-surrounding, i.e. his-
topathologically tumor-free renal tissue [8-10,18,20].
Moreover, a quantitative study found no difference
between normal and tumoral tissue regarding the fre-
quency of methylation or a normalized methylation index
of both tissues [11]. Therefore, as long as a significant
Analyzed promoter region of the RASSF1A gene Figure 1
Analyzed promoter region of the RASSF1A gene. CpG 
sites in the promoter region of the RASSF1A gene analyzed by 
combined bisulfite restriction analysis (COBRA) and bisulfite 
sequence analysis. Numbers refer to the position of tran-
scription start site while bracketed numbers indicate CpG 
sites. Solid triangles show TaqI restrictions sites used for 
COBRA. The solid and dashed lines indicate sequences 
amplified for COBRA and sequence analysis following 
bisulfite conversion of DNA. Inner primer positions were 
indicated by solid arrows.
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Methylation analysis of paired tumor and normal kidney sam- ples using COBRA Figure 2
Methylation analysis of paired tumor and normal kid-
ney samples using COBRA. The degree of methylation in 
kidney samples was analyzed using COBRA and video densit-
ometry for determination of methylated (M) and unmethyl-
ated (U) band signals: L, length marker; C1, negative 
methylation control (plasmid pCU); C2, positive methylation 
control (plasmid pCM); CO, negative control; T1 – T3, 
tumoral and P1 – P3, normal paired tissue samples.Molecular Cancer 2007, 6:49 http://www.molecular-cancer.com/content/6/1/49
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increase of tumor-dependent RASSF1A methylation can-
not be shown in CC-RCC, it seems debatable whether
RASSF1A substantially contributes to RCC tumorigenesis.
Our study is the first to specifically address the compari-
son of RASSF1A methylation levels detectable in paired
samples of normal and tumor tissue. Our quantitative
methylation analysis focused CpG sites localized directly
adjacent to the start of RASSF1A transcription, a promoter
region that has been described to cause gene silencing of
RASSF1A  [21,22]. The results of our quantitative data
clearly show that the degree of relative methylation is sig-
nificantly increased within tumor tissue of individual tis-
sue pairs. However, a single tissue pair out of 45
demonstrated a 7% decrease of relative methylation in the
tumor sample which we hypothetically explain by tissue
heterogeneity due to the presence of undetected fibrob-
lasts or tumor infiltrating lymphocytes.
Increased methylation as detected in most tumors can be
explained by a higher proportion of low grade methyla-
tion, an increased number of highly methylated promot-
ers or a combination of both effects. According to our
bisulfite sequencing analysis of both an individual tissue
pair and the tumor and normal groups as a whole, the
higher degree of relative methylation observed in tumors
can be attributed clearly to a higher proportion of densely
methylated sequences present in tumors. Although the
absolute numbers for the relative degree of methylation
determined by COBRA and calculated on the basis of
bisulfite sequencing slightly differ, a nearly identical ratio
of methylation in tumor vs. normal tissue samples was
obtained for both methods. Thus, the results of our com-
parative methylation analysis demonstrate a statistically
significant expansion of RASSF1A promoter methylation
in the course of RCC development.
However, our sequencing analyses also demonstrated that
dense methylation, though detected more frequently in
tumor cells, is also sporadically observed in normal tissue
thereby confirming results described in some of the earlier
analyses of RASSF1A  methylation in kidney tissue
[8,18,19]. Moreover, methylation data obtained for
tumors and normal tissue overall matches the results of
our expression analysis. Accordingly, expression analysis
demonstrated strong signals for RASSF1A protein in the
control cell line as well as in the cytoplasm of most of the
normal tubular cells. In contrast, a significant loss of pro-
tein was detected within most cells of tumor tissue. Thus,
protein levels detected immunohistochemically in a large
Results of quantitative methylation analysis of tissue pairs Figure 3
Results of quantitative methylation analysis of tissue pairs. a. Primary data and box plot illustration for in group com-
parison of relative methylation of RASSF1A promoter as measured by COBRA in 45 tumor and paired normal renal tissue sam-
ples as well as plasmid – DNA negative controls. Note that 44 (98%) tumors and 44 (98%) of 45 paired normal tissues 
demonstrated relative methylation greater than 2.75% determined as limit of analytical sensitivity. b. Quantitative methylation 
analysis of the RASSF1A promoter in 45 tumoral and normal tissue pairs using combined bisulfite restriction analysis (COBRA). 
Note that most of the tumors demonstrate a substantial relative increase in methylation when compared to their correspond-
ing normal tissue (P < 0.001)
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part of tumors are in concordance with a gene silencing of
RASSF1A in RCC as described previously [8-10].
Most interestingly, we also observed in normal tissue sam-
ples a partial loss of signals for RASSF1A protein, appear-
ing as a heterogeneous staining pattern, which is in line
with the detection of a subgroup of densely methylated
promoter sequences in normal tissue. Similar findings
have been described for methylation and expression of
Bisulfite sequence analysis of RASSF1A promoter methylation  in one tissue pair of tumoral and normal tissue Figure 4
Bisulfite sequence analysis of RASSF1A promoter 
methylation in one tissue pair of tumoral and normal 
tissue. RASSF1A promoter amplicons obtained from a single 
tumoral (T) and its paired normal (P) tissue sample were sub-
cloned and each 50 clones analyzed by the use of bisulfite 
sequencing. For each clone the methylation status of ana-
lyzed CpG sites is shown (solid circles: methylation, open cir-
cles: no methylation). Numbers on x-axis refer to base pair 
positions as indicated in Figure 1. Asterisks indicate ampli-
cons derived from densely methylated promoters demon-
strating at least 11 methylated CpG sites.
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Bisulfite sequencing of pooled tumoral and normal RASSF1A  promoters Figure 5
Bisulfite sequencing of pooled tumoral and normal 
RASSF1A promoters. RASSF1A promoter amplicons from 
42 tumoral and 42 normal tissue samples were normalized, 
pooled, subcloned and each 40 subclones of the tumor (T) 
and normal (P) group analyzed by bisulfite sequencing. For 
each clone the methylation status of analyzed CpG sites is 
shown (solid circles: methylation, open circles: no methyla-
tion). Numbers on x-axis refer to base pair positions as indi-
cated in Figure 1. Asterisks indicate amplicons derived from 
densely methylated promoters demonstrating at least 11 
methylated CpG sites.
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Detection of RASSF1A protein in clear cell RCC and control cell lines Figure 6
Detection of RASSF1A protein in clear cell RCC and control cell lines. Paraffin-embedded tissue samples obtained 
from renal tumor and paired normal tissues were analyzed for presence of RASSF1A protein using immunohistochemistry 
(counterstaining hematoxylin). a. Immunohistochemical positive control: CaSki cell line demonstrating absence of RASSF1A pro-
moter methylation in COBRA (see box; U, unmethylated signals; M, methylation signals) and immunopositivity depending on 
the absence (i) or presence (ii) of an antibody blocking peptide, respectively. b. Immunohistochemical negative control: HEK293 
cell line showing strong methylation in COBRA (see box; U, unmethylated signals; M, methylation signals). Only residual unspe-
cific nuclear immunopositivity can be observed, which is independent from the absence (i) and presence (ii) of an antibody 
blocking peptide. c. Tumor cells of a clear cell RCC (magnification, 400×). d. Histopathologically normal tissue with immunop-
ositive epithelial tubular cells (magnification, 400×). e. Heterogeneous staining patterns demonstrating immunopositive (i) and -
negative (ii) epithelia in renal tubules. f. Mosaic-like staining signals in a single tubular epithelium (see arrows, magnified from 
panel d as indicated).Molecular Cancer 2007, 6:49 http://www.molecular-cancer.com/content/6/1/49
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the MLH1 and p14 genes and were designated as "epige-
netic mosaicism" [23-25].
It has been described that RASSF1A translocates during
mitosis and reorganization of microtubules [14], thus
leading to a loss of cytoplasmic signals. However, appar-
ent mitotic activity was not detected in these cells, neither
in extent nor in frequency explaining the observed expres-
sion patterns.
We therefore conclude that the sporadic hypermethyla-
tion observed in normal tissue corresponds to a partial
loss of RASSF1A expression in normal tubular epithelium
of the kidney leading to epigenetic mosaicism of RASSF1A
as a possible premalignant event in CC-RCC tumorigene-
sis. To characterize the role of RASSF1A in early tumori-
genesis of the kidney further functional studies are
required.
Conclusion
Our methylation and expression analyses of RASSF1A
support the hypothesis that infrequent hypermethylation
of the RASSF1A promoter in normal cells precedes the for-
mation of tumor cells, thus explaining the more fre-
quently detected hypermethylation found in most CC-
RCCs. The partial loss of RASS1A expression driven by
hypermethylation of the gene promoter could be a prema-
lignant event in early tumorigenesis in the kidney.
Methods
Tissue samples and DNA extraction
Paired tumoral and normal specimens were prepared
from 45 primary clear cell RCCs after nephrectomy (table
1 for patient characteristics). Normal tissue samples were
obtained from histologically benign renal parenchyma
distant to the tumor-bearing region of the kidney. All tis-
sue samples were snap-frozen in liquid nitrogen and
stored at -80°C. Following preparation of 5 μm frozen
sections and hematoxylin-eosin staining, two serial cut-
tings of each appropriate tissue – i.e. tumor tissue consist-
ing at least of 75% tumor cells and histopathologically
normal tissue – were subjected to proteinase K digestion.
One section was dedicated to control quality and quantity
of extracted DNA using agarose gel electrophoresis and
videodensitometrical analysis. The remaining aliquot was
utilized for subsequent bisulfite conversion. In summary,
tissue sections were incubated on the slide using 0.5 mg
proteinase K in 50 μL of digestion buffer (50 mM KCl, 10
mM Tris-HCl pH 8.3, 0.5 mM EDTA, 0.01% w/v gelatin,
0.5% Tween 20) for 20 min at room temperature in a
humid chamber. Digestion of tissue sections was com-
pleted after transfer of partially digested sections into a 1.5
mL reaction tube and incubation at 50°C for another 3 h.
DNA was extracted using standard phenol/chloroform
extraction and phase lock tubes (Light 0.5 mL, Eppendorf,
Wesseling-Berzdorf, Germany) for phase separation.
Bisulfite conversion of DNA
Bisulfite conversion of genomic DNA was carried out
according to Herman et al. [26]. To precipitate the con-
verted DNA, the conversion mixture, 800 μl water, 1 μg
salmon sperm DNA, 20 μL MgCl2 (1 M) and 800 μL of
polyethylene glycol (PEG) 1,500 was mixed by inversion,
incubated for 1 h at 0°C and centrifuged for 20 min
(15,000 g, 4°C). Finally, the precipitated DNA was dis-
solved and desulfonated by addition of 100 μL NaOH
(0.3 M) and incubation at room temperature for 15 min.
Following standard ethanol precipitation the DNA was
resuspended in 50 μL Tris-EDTA buffer (10 mM, pH 8.0)
and stored at -80°C.
Methylation analysis
CpG sites in RASSF1A promoter region analyzed by com-
bined bisulfite restriction analysis (COBRA) and bisulfite
sequence analysis are shown in Figure 1. Plasmids pCM
(converted methylated) and pCU (converted unmethyl-
ated), were generated by cloning amplicons of methylated
and unmethylated native promoter sequence following
bisulfite conversion and then applied as reference
sequences for quantitative methylation analysis.
Combined bisulfite restriction analysis was carried out
using semi-nested PCR and primers as described previ-
ously [21]. A uniform amplification of the converted
methylated and unmethylated sequences could be main-
tained for copy numbers equal or greater than 5 × 103
sequence copies (data not shown). For first round ampli-
fication 5 μL of converted DNA, 0.4 μM of each primer,
CU001 (5'-GTT TTG GTA GTT TAA TGA GTT TAG GTT
TTT T-3') and CL002 (5'-ACC CTC TTC CTC TAA CAC
AAT AAA ACT AAC C-3'), 1 unit Taq polymerase (Quia-
gen, Hilden, Germany), 0.2 mM dNTPs and 5.5 μL of reac-
tion buffer were mixed (total volume 50 μL) and
subjected to PCR (initial denaturation at 95°C for 180 sec;
25 cycles with 45 sec of denaturation at 95°C, annealing
at 63°C for 1 min, primer extension at 73°C for 45 sec
and 180 sec at 72°C for the last cycle). The second PCR
product was generated using 1 μL of first PCR product and
primers CU001 and CN003 (5'-CCC CAC AAT CCC TAC
ACC CAA AT-3'). PCR conditions were identical to the
first PCR except an annealing temperature of 56°C was
applied in a total PCR volume of 25 μL. For restriction
digest 10 μL of the second PCR, 3.3 units of Taq I (New
England Biolabs, USA), water and the corresponding
restriction buffer were incubated over night at 65°C in a
final volume of 20 μL and subsequently analyzed using
PAGE and video densitometry.Molecular Cancer 2007, 6:49 http://www.molecular-cancer.com/content/6/1/49
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To determine the relative degree of methylation, frag-
ments corresponding to methylated sequences and the
uncut band indicating unmethylated sequences were
quantified by video densitometry and corrected for
molecular weight. The relative degree of methylation in
each sample was calculated by dividing the sum of meth-
ylated signals by the sum of all signals. To demonstrate
that COBRA can be applied for determination of the rela-
tive degree of RASSF1A promoter methylation, defined
mixtures of corresponding plasmid DNA and of DNA iso-
lated from HEK293 and CaSki cell lines were measured.
The relative degree of methylation measured by COBRA
was then compared to the known input ratio of methyl-
ated and unmethylated sequences. Linearity was observed
for almost two orders of magnitude, both for the plasmid
and cell line controls. Using the threefold standard devia-
tion of signals obtained from multiple negative controls,
the analytical sensitivity of COBRA could be calculated to
be 2.75% relative methylation (Fig. 3a).
Bisulfite sequencing
For sequence analysis amplicons were subcloned into
pGEM-T Easy vectors (Promega, Mannheim, Germany)
and sequenced using SP6 primer, BigDye Terminator v1.1
Cycle Sequencing Kit on an ABI 3100 Avant automated
sequencer (Applied Biosystems, Darmstadt, Germany)
according to the manufacturer's protocols or by custom
sequence analysis (MWG Biotech, Ebersberg, Germany).
Pool sequencing analysis was carried out following nor-
malization of 42 amplicons obtained each from the
tumor and normal tissue groups and subcloning as
described above.
Immunohistochemistry
Immunohistochemical analysis of renal paraffin embed-
ded tissue samples arranged in an array format and signal
amplification using tyramide was carried out as described
previously [27-29]. For detection of RASSF1A protein an
affinity purified goat polyclonal antibody (RASF1-N15,
Santa Cruz Biotechnology, USA) and a mouse mono-
clonal antibody (Anti-human RASSF1A mAb, clone 3F3,
Acris, Germany) were applied. RASF1-N15 specifically
detects the N-terminus of RASSF1 isoforms A, D, F, G.
However, the major transcripts are represented by iso-
forms A and C [21], whereas other isoforms seem to be
expressed rarely in a tissue-specific manner such as
RASSF1D and E [30]. Expression of RASSF isoform C has
been localized to the nucleus [14], thus cytoplasmic sig-
nals obtained by immunostaining using RASF1-N15 anti-
body were considered to be due to RASSF1A expression.
Statistical analysis
Statistical analyses were performed using the SPSS statisti-
cal software (statistical package for social sciences, SPSS,
Inc., Chicago, IL). P-values of ≤0.05 were considered sta-
tistically significant.
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